Abstract
Considering the recent study by Dobrowolska et al, which investigated sex-related differences in treatment outcomes for chronic hepatitis C infection, this letter endorses the findings that highlight significant disparities between male and female patients. The study revealed that women, particularly those in the premenopausal and menopausal stages, exhibited higher sustained virologic response rates than men. However, postmenopausal women encounter unique challenges that merit attention. This letter emphasizes the necessity for healthcare providers to implement sex-sensitive approaches in the management of hepatitis C, acknowledging the impact of biological, hormonal, and psychosocial factors on treatment efficacy. By advocating tailored treatment strategies that address these disparities, we can improve patient outcomes and ensure equitable healthcare for all individuals affected by hepatitis C. Furthermore, this letter calls for additional research to explore the underlying mechanisms driving these differences, ultimately contributing to more effective and personalized care of patients across diverse demographics.